1. Home
  2. HCM
  3. HCM News

Latest HUTCHMED (China) Limited (HCM) News on December 18, 2024

HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib)
HCM

GlobeNewswire

6 days ago

HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib)

HUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor Therapy
HCM

GlobeNewswire

7 days ago

HUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor Therapy

Innovent and HUTCHMED Jointly Announce NMPA Conditional Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Advanced Endometrial Cancer
HCM

PR Newswire

15 days ago

Innovent and HUTCHMED Jointly Announce NMPA Conditional Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Advanced Endometrial Cancer

HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer
HCM

GlobeNewswire

15 days ago

HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer

HUTCHMED Announces Continued Inclusion of ORPATHYS® (savolitinib) in the National Reimbursement Drug List in China at Current Terms
HCM

GlobeNewswire

20 days ago

HUTCHMED Announces Continued Inclusion of ORPATHYS® (savolitinib) in the National Reimbursement Drug List in China at Current Terms

HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan
HCM

GlobeNewswire

a month ago

HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee
HCM

GlobeNewswire

a month ago

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

HUTCHMED Highlights Clinical Data to be Presented at the 2024 ASH Annual Meeting and the 2024 ESMO Asia Congress
HCM

GlobeNewswire

a month ago

HUTCHMED Highlights Clinical Data to be Presented at the 2024 ASH Annual Meeting and the 2024 ESMO Asia Congress

HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® (fruquintinib) Sales by Takeda
HCM

GlobeNewswire

2 months ago

HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® (fruquintinib) Sales by Takeda

HUTCHMED Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial
HCM

GlobeNewswire

2 months ago

HUTCHMED Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial

HUTCHMED (China) Ltd (HCM) (Q2 2024) Earnings Call Highlights: Strong US Sales Propel Growth ...
HCM

GuruFocus.com

2 months ago

HUTCHMED (China) Ltd (HCM) (Q2 2024) Earnings Call Highlights: Strong US Sales Propel Growth ...

HUTCHMED (China) (LON:HCM) shareholders are up 17% this past week, but still in the red over the last three years
HCM

Simply Wall St.

3 months ago

HUTCHMED (China) (LON:HCM) shareholders are up 17% this past week, but still in the red over the last three years

Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing
HCM

GlobeNewswire

3 months ago

Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing

HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda
HCM

GlobeNewswire

3 months ago

HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024
HCM

GlobeNewswire

3 months ago

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024
HCM

GlobeNewswire

3 months ago

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024
HCM

GlobeNewswire

3 months ago

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024

HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung Cancer
HCM

GlobeNewswire

3 months ago

HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung Cancer

HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China
HCM

GlobeNewswire

4 months ago

HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China

HUTCHMED (China) Limited (HCM): A Cheap Pharmaceutical Stock to Buy According to Short Sellers
HCM

Insider Monkey

4 months ago

HUTCHMED (China) Limited (HCM): A Cheap Pharmaceutical Stock to Buy According to Short Sellers

HUTCHMED to Host Expert Call to discuss Immune Thrombocytopenia
HCM

GlobeNewswire

4 months ago

HUTCHMED to Host Expert Call to discuss Immune Thrombocytopenia

HUTCHMED Reports 2024 Interim Results and Provides Business Updates
HCM

GlobeNewswire

5 months ago

HUTCHMED Reports 2024 Interim Results and Provides Business Updates

HUTCHMED (China) Limited's (LON:HCM) last week's 6.4% decline must have disappointed private equity firms who have a significant stake
HCM

Simply Wall St.

5 months ago

HUTCHMED (China) Limited's (LON:HCM) last week's 6.4% decline must have disappointed private equity firms who have a significant stake

HUTCHMED Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review Status
HCM

GlobeNewswire

5 months ago

HUTCHMED Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review Status

HUTCHMED to Announce 2024 Half-Year Financial Results
HCM

GlobeNewswire

6 months ago

HUTCHMED to Announce 2024 Half-Year Financial Results

Save the Date: HUTCHMED to Present R&D Updates on July 9, 2024
HCM

GlobeNewswire

6 months ago

Save the Date: HUTCHMED to Present R&D Updates on July 9, 2024

HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda
HCM

GlobeNewswire

6 months ago

HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda

HUTCHMED Highlights Publication of Phase III ESLIM-01 Results in The Lancet Haematology
HCM

GlobeNewswire

6 months ago

HUTCHMED Highlights Publication of Phase III ESLIM-01 Results in The Lancet Haematology

HUTCHMED Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China
HCM

GlobeNewswire

6 months ago

HUTCHMED Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China

HUTCHMED Highlights Publication of Phase III FRUTIGA Results in Nature Medicine
HCM

GlobeNewswire

7 months ago

HUTCHMED Highlights Publication of Phase III FRUTIGA Results in Nature Medicine

HUTCHMED Highlights Presentations at the 2024 ASCO Annual Meeting
HCM

GlobeNewswire

7 months ago

HUTCHMED Highlights Presentations at the 2024 ASCO Annual Meeting

HUTCHMED announces retirement of Chairman, appointment of new Chairman and change of members of board committees
HCM

GlobeNewswire

7 months ago

HUTCHMED announces retirement of Chairman, appointment of new Chairman and change of members of board committees

HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress
HCM

GlobeNewswire

7 months ago

HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress

HUTCHMED Initiates the RAPHAEL Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China
HCM

GlobeNewswire

7 months ago

HUTCHMED Initiates the RAPHAEL Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China

HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui
HCM

GlobeNewswire

7 months ago

HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee
HCM

GlobeNewswire

7 months ago

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda
HCM

GlobeNewswire

8 months ago

HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda

HUTCHMED (China) (LON:HCM) shareholders are up 8.2% this past week, but still in the red over the last five years
HCM

Simply Wall St.

8 months ago

HUTCHMED (China) (LON:HCM) shareholders are up 8.2% this past week, but still in the red over the last five years

HUTCHMED Highlights Data to be Presented at AACR Congress 2024
HCM

GlobeNewswire

8 months ago

HUTCHMED Highlights Data to be Presented at AACR Congress 2024

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status
HCM

GlobeNewswire

9 months ago

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status

Do Its Financials Have Any Role To Play In Driving HUTCHMED (China) Limited's (LON:HCM) Stock Up Recently?
HCM

Simply Wall St.

9 months ago

Do Its Financials Have Any Role To Play In Driving HUTCHMED (China) Limited's (LON:HCM) Stock Up Recently?

HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC
HCM

GlobeNewswire

9 months ago

HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC

HUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China
HCM

GlobeNewswire

9 months ago

HUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China

HUTCHMED (China) Full Year 2023 Earnings: EPS: US$0.12 (vs US$0.43 loss in FY 2022)
HCM

Simply Wall St.

10 months ago

HUTCHMED (China) Full Year 2023 Earnings: EPS: US$0.12 (vs US$0.43 loss in FY 2022)

HUTCHMED Reports 2023 Full Year Results and Provides Business Updates
HCM

GlobeNewswire

10 months ago

HUTCHMED Reports 2023 Full Year Results and Provides Business Updates

HUTCHMED Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer at ASCO Plenary Series Session
HCM

GlobeNewswire

10 months ago

HUTCHMED Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer at ASCO Plenary Series Session

HUTCHMED Announces that Inmagene Exercises Option to License Two Drug Candidates as Part of Strategic Partnership
HCM

GlobeNewswire

a year ago

HUTCHMED Announces that Inmagene Exercises Option to License Two Drug Candidates as Part of Strategic Partnership

Revolution Medicines to Participate in Upcoming Investor Conferences
HCM

GlobeNewswire

a year ago

Revolution Medicines to Participate in Upcoming Investor Conferences

HUTCHMED to Announce 2023 Final Results
HCM

GlobeNewswire

a year ago

HUTCHMED to Announce 2023 Final Results

What to Expect From Meritage Homes' (MTH) Q4 Earnings?
HCM

Zacks

a year ago

What to Expect From Meritage Homes' (MTH) Q4 Earnings?

HUTCHMED Receives ELUNATE® (fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer
HCM

GlobeNewswire

a year ago

HUTCHMED Receives ELUNATE® (fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer

Should You Hold Warrior Met Coal (HCC)?
HCM

Insider Monkey

a year ago

Should You Hold Warrior Met Coal (HCC)?

WSFS Financial Corporation (NASDAQ:WSFS) Q4 2023 Earnings Call Transcript
HCM

Insider Monkey

a year ago

WSFS Financial Corporation (NASDAQ:WSFS) Q4 2023 Earnings Call Transcript

Down 82%, 1 Warren Buffett Growth Stock to Buy in 2024
HCM

Motley Fool

a year ago

Down 82%, 1 Warren Buffett Growth Stock to Buy in 2024

Forget Upstart Stock: 2 Stocks to Buy Hand Over Fist Instead
HCM

Motley Fool

a year ago

Forget Upstart Stock: 2 Stocks to Buy Hand Over Fist Instead

Spire Declares Dividend
HCM

PR Newswire

a year ago

Spire Declares Dividend

Virtu Financial (VIRT) Lags Q4 Earnings and Revenue Estimates
HCM

Zacks

a year ago

Virtu Financial (VIRT) Lags Q4 Earnings and Revenue Estimates

Griffon (GFF) Beats Stock Market Upswing: What Investors Need to Know
HCM

Zacks

a year ago

Griffon (GFF) Beats Stock Market Upswing: What Investors Need to Know

Stocks to Buy: 3 Sleeping Giants About to Wake Up and Soar
HCM

InvestorPlace

a year ago

Stocks to Buy: 3 Sleeping Giants About to Wake Up and Soar

H.B. Fuller Announces Quarterly Dividend
HCM

Business Wire

a year ago

H.B. Fuller Announces Quarterly Dividend

2 of the Best Stocks to Buy on a Dip in 2024
HCM

Motley Fool

a year ago

2 of the Best Stocks to Buy on a Dip in 2024

Household Products Stocks Q3 Teardown: Church & Dwight (NYSE:CHD) Vs The Rest
HCM

StockStory

a year ago

Household Products Stocks Q3 Teardown: Church & Dwight (NYSE:CHD) Vs The Rest

Celanese (CE) & Under Armour Partner to Develop Sustainable Fiber
HCM

Zacks

a year ago

Celanese (CE) & Under Armour Partner to Develop Sustainable Fiber

Clearway Energy, Inc. to Report Fourth Quarter 2023 Financial Results on February 22, 2024
HCM

GlobeNewswire

a year ago

Clearway Energy, Inc. to Report Fourth Quarter 2023 Financial Results on February 22, 2024

Axcelis Technologies (ACLS) Exceeds Market Returns: Some Facts to Consider
HCM

Zacks

a year ago

Axcelis Technologies (ACLS) Exceeds Market Returns: Some Facts to Consider

DigitalOcean's (DOCN) Expanding Portfolio Strengthens Prospect
HCM

Zacks

a year ago

DigitalOcean's (DOCN) Expanding Portfolio Strengthens Prospect

Celanese and Under Armour Develop Innovative New NEOLAST™ Fiber for Use in Performance Stretch Fabrics
HCM

Business Wire

a year ago

Celanese and Under Armour Develop Innovative New NEOLAST™ Fiber for Use in Performance Stretch Fabrics

HCM

Reuters

a year ago

CORRECTED-SEC probes B. Riley deals with client tied to failed hedge fund - Bloomberg News

3 Top-Rated Russell 2000 Stocks Wall Street Analysts Are Loving Now: January 2024
HCM

InvestorPlace

a year ago

3 Top-Rated Russell 2000 Stocks Wall Street Analysts Are Loving Now: January 2024

Zacks Market Edge Highlights: MODG, BALY, FNKO, IIPR and DFIN
HCM

Zacks

a year ago

Zacks Market Edge Highlights: MODG, BALY, FNKO, IIPR and DFIN

Independence Realty Trust Announces Fourth Quarter and Full Year 2023 Earnings Release and Conference Call Dates
HCM

Business Wire

a year ago

Independence Realty Trust Announces Fourth Quarter and Full Year 2023 Earnings Release and Conference Call Dates

Should You Buy Small Cap Stocks Right Now?
HCM

Zacks

a year ago

Should You Buy Small Cap Stocks Right Now?

Halozyme Announces argenx Received Approval in Japan for VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Co-Formulated with ENHANZE® for Generalized Myasthenia Gravis
HCM

PR Newswire

a year ago

Halozyme Announces argenx Received Approval in Japan for VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Co-Formulated with ENHANZE® for Generalized Myasthenia Gravis

Q3 Household Products Earnings Review: First Prize Goes to Clorox (NYSE:CLX)
HCM

StockStory

a year ago

Q3 Household Products Earnings Review: First Prize Goes to Clorox (NYSE:CLX)

Fluence Surpasses 20 GWh of Deployed and Contracted Battery-based Energy Storage Systems Globally
HCM

GlobeNewswire

a year ago

Fluence Surpasses 20 GWh of Deployed and Contracted Battery-based Energy Storage Systems Globally

Why Urban Outfitters (URBN) is a Top Value Stock for the Long-Term
HCM

Zacks

a year ago

Why Urban Outfitters (URBN) is a Top Value Stock for the Long-Term

Silicon Labs Announces Fourth Quarter 2023 Earnings Webcast
HCM

PR Newswire

a year ago

Silicon Labs Announces Fourth Quarter 2023 Earnings Webcast

Fluence Mosaic Intelligent Bidding Software Expands to Optimize Hybrid Renewables and Storage Assets in California Independent System Operator Wholesale Power Market
HCM

GlobeNewswire

a year ago

Fluence Mosaic Intelligent Bidding Software Expands to Optimize Hybrid Renewables and Storage Assets in California Independent System Operator Wholesale Power Market

Fade to Black: 3 Coal Stocks to Offload as the Industry Shifts
HCM

InvestorPlace

a year ago

Fade to Black: 3 Coal Stocks to Offload as the Industry Shifts

16 Best Mid-Cap Growth Stocks To Buy Now
HCM

Insider Monkey

a year ago

16 Best Mid-Cap Growth Stocks To Buy Now

Marqeta to Announce Fourth Quarter and Full Year 2023 Results on February 28, 2024
HCM

Business Wire

a year ago

Marqeta to Announce Fourth Quarter and Full Year 2023 Results on February 28, 2024

Winners And Losers Of Q3: JFrog (NASDAQ:FROG) Vs The Rest Of The Software Development Stocks
HCM

StockStory

a year ago

Winners And Losers Of Q3: JFrog (NASDAQ:FROG) Vs The Rest Of The Software Development Stocks

COPT Defense Exceeds Development Leasing Guidance and Vacancy Leasing Target in 2023
HCM

Business Wire

a year ago

COPT Defense Exceeds Development Leasing Guidance and Vacancy Leasing Target in 2023

HUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status
HCM

GlobeNewswire

a year ago

HUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status

Should You Investigate Spectrum Brands Holdings, Inc. (NYSE:SPB) At US$78.99?
HCM

Simply Wall St.

a year ago

Should You Investigate Spectrum Brands Holdings, Inc. (NYSE:SPB) At US$78.99?

Cousins Properties Announces Dates for Fourth Quarter 2023 Earnings Release and Conference Call
HCM

PR Newswire

a year ago

Cousins Properties Announces Dates for Fourth Quarter 2023 Earnings Release and Conference Call

Five Below (FIVE) Holiday Sales Rise, Eyes Solid Finish to FY23
HCM

Zacks

a year ago

Five Below (FIVE) Holiday Sales Rise, Eyes Solid Finish to FY23

Returns On Capital At Certara (NASDAQ:CERT) Have Stalled
HCM

Simply Wall St.

a year ago

Returns On Capital At Certara (NASDAQ:CERT) Have Stalled

13 Most Advanced Countries in Electronics
HCM

Insider Monkey

a year ago

13 Most Advanced Countries in Electronics

5 Great REITs To Buy In 2024
HCM

Benzinga

a year ago

5 Great REITs To Buy In 2024

A Closer Look at California Resources' Intriguing Business Profile
HCM

GuruFocus.com

a year ago

A Closer Look at California Resources' Intriguing Business Profile

15 Best Growth Stocks to Buy Under $25
HCM

Insider Monkey

a year ago

15 Best Growth Stocks to Buy Under $25

H World Group Limited Announces the Change of Officers
HCM

GlobeNewswire

a year ago

H World Group Limited Announces the Change of Officers

Those who invested in AeroVironment (NASDAQ:AVAV) five years ago are up 73%
HCM

Simply Wall St.

a year ago

Those who invested in AeroVironment (NASDAQ:AVAV) five years ago are up 73%

Investors in Leggett & Platt (NYSE:LEG) have unfortunately lost 31% over the last three years
HCM

Simply Wall St.

a year ago

Investors in Leggett & Platt (NYSE:LEG) have unfortunately lost 31% over the last three years

Beyond Meat: How the plant-based CEO leads an uphill battle
HCM

Yahoo Finance Video

a year ago

Beyond Meat: How the plant-based CEO leads an uphill battle

AECOM (ACM) Wins Contract From Metrolinx, Boosts Backlog
HCM

Zacks

a year ago

AECOM (ACM) Wins Contract From Metrolinx, Boosts Backlog

High-Yield Heroes: The Top 3 Dividend Stocks in My Portfolio
HCM

InvestorPlace

a year ago

High-Yield Heroes: The Top 3 Dividend Stocks in My Portfolio

agilon health to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
HCM

Business Wire

a year ago

agilon health to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

Vertex Announces New Leadership with Three Strategic Appointments in Customer Success and Services, Tax Research and Global Talent
HCM

GlobeNewswire

a year ago

Vertex Announces New Leadership with Three Strategic Appointments in Customer Success and Services, Tax Research and Global Talent

Share on Social Networks: